A comprehensive, medically reviewed reference on Levitra (vardenafil) — covering its pharmacology, FDA approval, dosage, how it compares to Viagra and Cialis, critical drug interactions, and safe access for patients in the United States and worldwide.
Medically reviewed by a Licensed Clinical Pharmacist | Last updated: June 2026 | References listed at end of article
| Generic Name | Vardenafil |
| Brand Names | Levitra · Staxyn (orally disintegrating tablet form) |
| Drug Class | Phosphodiesterase type 5 (PDE5) inhibitor |
| FDA Approval | Yes — August 2003 (erectile dysfunction in adult men) |
| DEA Schedule | Not a controlled substance |
| Available Doses | 2.5 mg · 5 mg · 10 mg · 20 mg (tablets) · 10 mg (Staxyn ODT) |
| Standard Starting Dose | 10 mg taken 25–60 minutes before sexual activity |
| Onset of Action | 25–60 minutes |
| Duration of Effect | 4–5 hours |
| Half-Life | 4–5 hours (vardenafil); ~11–13 hours (active metabolite) |
| Taken With Food | Can be taken with or without food. Avoid high-fat meals — delays absorption. |
| Related Drugs | Sildenafil (Viagra) · Tadalafil (Cialis) · Avanafil (Stendra) |
| Critical Interaction | Nitrates — absolute contraindication. Can cause fatal hypotension. |
| Generic Available | Yes — widely available in the USA since 2018 |
Levitra is the brand name for vardenafil hydrochloride — a prescription oral medication approved by the U.S. Food and Drug Administration in August 2003 for the treatment of erectile dysfunction (ED) in adult men. It belongs to the phosphodiesterase type 5 (PDE5) inhibitor class of drugs, the same pharmacological class as sildenafil (Viagra), tadalafil (Cialis), and avanafil (Stendra) — a class that fundamentally changed the clinical management of erectile dysfunction following Viagra's landmark 1998 approval.
Levitra was developed by Bayer Pharmaceuticals in partnership with GlaxoSmithKline and Schering-Plough, positioned as a second-generation PDE5 inhibitor with a faster onset and a more targeted receptor selectivity profile than sildenafil. A second formulation — Staxyn — was subsequently approved in 2010 as an orally disintegrating tablet (ODT) version of vardenafil at a fixed 10 mg dose, designed for patients who prefer not to swallow a standard tablet, offering the convenience of dissolving directly on the tongue without water.
Following the expiration of the original patent, generic vardenafil entered the U.S. market in 2018, making the medication significantly more accessible and affordable. Generic vardenafil tablets are bioequivalent to branded Levitra and are the standard dispensed formulation in most pharmacy settings today. Both branded and generic versions are widely prescribed across the United States, Europe, Australia, and most other major healthcare markets.
Erectile dysfunction is one of the most prevalent male health conditions globally — affecting an estimated 30 million men in the United States alone and over 150 million men worldwide according to data from the Massachusetts Male Aging Study and subsequent epidemiological reviews. Prevalence increases with age: approximately 40% of men at age 40 experience some degree of ED, rising to roughly 70% by age 70. It is increasingly recognized not merely as a quality-of-life issue but as a potential early clinical marker for underlying cardiovascular disease — a dimension that makes appropriate medical evaluation before pharmacological treatment particularly important.
A normal erection involves a precisely coordinated physiological sequence. Sexual stimulation triggers the release of nitric oxide (NO) in the corpus cavernosum — the spongy erectile tissue running the length of the penis. Nitric oxide activates guanylate cyclase, an enzyme that converts GTP to cyclic guanosine monophosphate (cGMP). Elevated cGMP relaxes the smooth muscle in penile arterial walls, allowing blood to flow into the corpus cavernosum, producing engorgement and erection. The enzyme phosphodiesterase type 5 (PDE5) naturally breaks down cGMP, terminating the erection.
Levitra works by selectively inhibiting PDE5, preventing the breakdown of cGMP. With PDE5 inhibited, cGMP accumulates — the smooth muscle remains relaxed, blood flow is maintained, and the erection is sustained in response to sexual stimulation. Critically, this mechanism is dependent on sexual arousal; Levitra does not produce erections independently of stimulation and has no effect in the absence of sexual excitement. It amplifies and sustains the natural physiological pathway rather than bypassing it.
Vardenafil is approximately 10 times more potent than sildenafil at the PDE5 receptor and demonstrates a somewhat more selective PDE5 inhibition profile — with lower activity at PDE6 (the retinal phosphodiesterase implicated in Viagra's visual side effects) and PDE1 (found in cardiac and vascular tissue). This selectivity profile is one reason vardenafil is associated with a lower incidence of visual disturbances compared to sildenafil, though this distinction is mild in practice at standard therapeutic doses.
After oral administration, vardenafil is absorbed rapidly, with peak plasma concentrations reached within 30 to 120 minutes. The onset of erectile response typically begins within 25 to 60 minutes. The medication's effect on PDE5 persists for approximately 4 to 5 hours — which represents the clinically relevant window for sexual activity. The plasma half-life of vardenafil itself is 4 to 5 hours; an active metabolite (M1) has a half-life of approximately 11 to 13 hours but contributes only modestly to overall clinical effect.
All four FDA-approved oral PDE5 inhibitors — sildenafil (Viagra), vardenafil (Levitra), tadalafil (Cialis), and avanafil (Stendra) — work through the same core mechanism of PDE5 inhibition. Their clinical differences lie primarily in onset speed, duration of action, selectivity profile, food interactions, and dosing flexibility. Understanding these distinctions is essential for matching the right agent to each patient's lifestyle and needs.
| Feature | Levitra (Vardenafil) | Viagra (Sildenafil) | Cialis (Tadalafil) | Stendra (Avanafil) |
|---|---|---|---|---|
| FDA Approval | 2003 | 1998 | 2003 | 2012 |
| Standard Dose | 10 mg | 50 mg | 10 mg (on-demand) · 2.5–5 mg (daily) | 100 mg |
| Dose Range | 2.5–20 mg | 25–100 mg | 2.5–20 mg | 50–200 mg |
| Onset | 25–60 min | 30–60 min | 30–60 min (up to 2 hr) | 15–30 min (fastest) |
| Duration of Effect | 4–5 hours | 4–6 hours | Up to 36 hours | Up to 6 hours |
| Half-Life | 4–5 hr (parent) · ~12 hr (metabolite) | 3–5 hr | 17.5 hr | 3–5 hr |
| Daily Dosing Option | No | No | Yes (2.5–5 mg/day) | No |
| High-Fat Meal Effect | Delays absorption — avoid | Delays absorption — avoid | Minimal effect | Minimal effect |
| Visual Side Effects | Low (low PDE6 selectivity) | Higher (more PDE6 activity) | Low | Very low |
| Alcohol Interaction | Moderate caution | Moderate caution | Moderate caution | Low interaction |
| Generic Available | Yes (since 2018) | Yes (since 2017) | Yes (since 2018) | No (brand only) |
| Nitrate Contraindication | Absolute | Absolute | Absolute | Absolute |
The most clinically significant differentiator among PDE5 inhibitors is tadalafil's exceptional duration of action — up to 36 hours, earning Cialis the colloquial descriptor "the weekend pill" — and its availability as a once-daily low-dose formulation that eliminates the need to time medication relative to sexual activity. For patients who prefer spontaneity without planning around a dosing window, daily tadalafil is often the preferred clinical choice. For patients who prefer on-demand dosing with the fastest possible onset, avanafil (Stendra) achieves meaningful effect in as little as 15 minutes. Levitra occupies a well-established middle position: a faster onset than standard sildenafil for some patients, a slightly more selective PDE5 profile, and a reliable 4–5 hour therapeutic window that suits structured on-demand use.
Choice between PDE5 inhibitors is highly individual. A patient who does not respond adequately to one agent may respond well to another, even at equivalent doses — a phenomenon well documented in clinical practice and acknowledged in urology guidelines. If Levitra has not produced the desired response, this should be discussed with the prescribing physician before concluding that PDE5 inhibitor therapy is ineffective.
Levitra is FDA-approved specifically and exclusively for the treatment of erectile dysfunction in adult men — defined as the consistent or recurrent inability to achieve or maintain an erection sufficient for satisfactory sexual performance. It is effective across the full spectrum of ED severity, from mild situational difficulty to moderate and severe erectile impairment, and across a broad range of underlying etiologies including psychogenic, vasculogenic, neurogenic, and mixed-cause ED.
Clinical trial data submitted for FDA approval demonstrated that Levitra produced significant improvements in the ability to achieve and maintain erections across all severity levels and in men with major comorbidities — including diabetes mellitus, hypertension, hyperlipidemia, and post-radical prostatectomy — populations where ED management is both more prevalent and more clinically complex. In the pivotal phase III trials, 65–80% of attempts at intercourse were successful with vardenafil compared to 30–52% with placebo, across all dose levels.
Erectile dysfunction in men with type 1 or type 2 diabetes is a particularly prevalent and clinically challenging presentation — affecting an estimated 35–75% of diabetic men, often beginning at a younger age and progressing more severely than in the general population, due to combined vascular, neurological, and hormonal mechanisms. Clinical trials of vardenafil in diabetic men with ED demonstrated consistent efficacy improvements across all measured endpoints, including the International Index of Erectile Function (IIEF), making it a recognized and guideline-supported option in this population.
Erectile dysfunction is an almost universal consequence of radical prostatectomy for prostate cancer, even with nerve-sparing surgical technique. The degree and duration of post-surgical ED depend heavily on surgical approach and patient-specific factors including age and pre-operative erectile function. Vardenafil has been studied specifically in this population and demonstrated meaningful improvements in erectile function during the recovery period, particularly in men who underwent bilateral nerve-sparing procedures and were treated early in the post-operative phase.
In men where ED is primarily driven by psychological factors — performance anxiety, relationship stress, depression, or low self-confidence — Levitra provides a reliable pharmacological foundation that interrupts the anxiety-performance cycle. By ensuring physiological success during the early phase of treatment, it allows many men to rebuild confidence to a degree that reduces psychological dependence on the medication over time. Pharmacological treatment is often most effective when combined with psychological support or sex therapy in psychogenic presentations.
Levitra is available in four tablet strengths — 2.5 mg, 5 mg, 10 mg, and 20 mg — as well as the Staxyn orally disintegrating tablet at a fixed 10 mg dose. The prescribing principle is consistent with all PDE5 inhibitor therapy: begin at the lowest dose likely to be effective and adjust based on individual response and tolerability.
| Standard Adult Starting Dose | 10 mg taken orally 25–60 minutes before anticipated sexual activity. Based on efficacy and tolerability, the dose may be increased to 20 mg or decreased to 5 mg. Maximum one dose per 24-hour period. |
| Maximum Dose | 20 mg once per 24 hours. Doses above 20 mg are not approved and provide no additional therapeutic benefit while substantially increasing adverse effect risk. |
| Elderly Patients (65+) | Start at 5 mg per dose. May increase to 10 mg or 20 mg based on response and tolerability. Older patients have approximately 40% higher vardenafil plasma exposure due to reduced hepatic clearance — making a conservative starting dose clinically appropriate. |
| Mild–Moderate Hepatic Impairment | Start at 5 mg per dose. Maximum 10 mg per dose. Levitra is not recommended in patients with severe hepatic impairment (Child-Pugh C), as pharmacokinetics have not been adequately studied in this group. |
| Renal Impairment | No dose adjustment required for mild-to-moderate renal impairment. Exercise caution in severe renal impairment (CrCl <30 mL/min); start at 5 mg and titrate carefully. |
| Staxyn (ODT form) | 10 mg orally disintegrating tablet. Place on the tongue; dissolves without water. Not interchangeable milligram-for-milligram with Levitra tablets — the ODT formulation produces approximately 21% higher Cmax than the standard tablet at the same dose. Do not cut, crush, or swallow whole. |
| Patients on Alpha-Blockers | Start at 5 mg. The combination of vardenafil and alpha-blockers produces additive blood pressure lowering — a lower starting dose reduces symptomatic hypotension risk. See Drug Interactions section. |
| Patients on Strong CYP3A4 Inhibitors | Maximum 2.5 mg per 72 hours when co-administered with strong CYP3A4 inhibitors (e.g., ketoconazole 400 mg, ritonavir). These agents dramatically elevate vardenafil plasma exposure. See Drug Interactions for full detail. |
Levitra is an on-demand medication — it is taken before sexual activity, not on a fixed daily schedule (unlike low-dose daily tadalafil). Taking more than one dose within any 24-hour period is not approved and substantially increases the risk of adverse cardiovascular, visual, and hemodynamic effects. If the standard 10 mg dose produces inadequate results, discuss dose adjustment with your prescribing physician rather than taking a second dose.
Levitra tablets should be swallowed whole with water, approximately 25 to 60 minutes before anticipated sexual activity. The medication can be taken with or without food, but high-fat meals should be avoided — a fatty meal delays the absorption of vardenafil significantly, reducing peak plasma concentrations by approximately 18–50% and extending the time to onset. A light meal or fasting produces the most predictable and reliable onset.
The Staxyn orally disintegrating tablet is placed directly on the tongue and allowed to dissolve without water or chewing. It should not be swallowed whole, and it should not be split or crushed. Patients should not eat or drink for 10 minutes after taking Staxyn to allow full dissolution and absorption. Staxyn is not interchangeable milligram-for-milligram with standard Levitra tablets due to formulation differences that produce modestly higher peak concentrations from the ODT form.
Sexual stimulation remains necessary for Levitra to produce an erection. The medication does not produce arousal, desire, or spontaneous erections in the absence of sexual stimulation — its role is to potentiate the natural physiological response when stimulation is present. Patients who expect the medication to operate without stimulation will experience an apparent lack of effect that does not reflect true treatment failure.
Grapefruit and grapefruit juice should be avoided while taking Levitra, as grapefruit inhibits CYP3A4 metabolism and can significantly increase vardenafil plasma concentrations, amplifying both therapeutic effect and adverse effects including blood pressure lowering. Alcohol consumption should be minimized — both Levitra and alcohol independently lower blood pressure, and their combination can produce symptomatic hypotension, dizziness, and flushing disproportionate to either alone.
Levitra's side effect profile at standard doses is consistent with its mechanism of action — most effects reflect PDE5 inhibition in vascular smooth muscle at sites beyond the corpus cavernosum. The majority of adverse effects are mild to moderate, dose-dependent, transient, and resolve without intervention.
Headache is the most frequently reported adverse effect across all PDE5 inhibitors, including vardenafil, occurring in approximately 15% of patients in clinical trials. It results from PDE5 inhibition in cerebral vasculature producing mild vasodilation. It is generally mild and responds well to standard analgesics. Facial flushing — a sensation of warmth and visible reddening of the face, neck, and upper chest — is the second most common effect, occurring in approximately 11% of patients, and results from the same peripheral vasodilatory mechanism. It is self-limiting, typically peaking within 30–60 minutes of dosing and resolving as plasma levels fall.
Nasal congestion occurs in approximately 9% of patients, again a consequence of local vasodilation in nasal mucosal vessels. Dyspepsia (heartburn or acid discomfort) is reported in approximately 4% of patients and may be mitigated by taking the medication with food. Dizziness — reflecting mild systemic blood pressure lowering — is reported in approximately 2% of patients at the standard 10 mg dose and more frequently at 20 mg. Back pain and myalgia (muscle aching) are reported at a lower frequency with vardenafil than with tadalafil, where these effects are particularly notable due to the longer half-life.
Visual disturbances — including mild and transient changes in color perception (a blue-green tinge to objects, most commonly), blurred vision, and increased light sensitivity — are reported at a lower incidence with vardenafil than with sildenafil, attributable to vardenafil's lower activity at PDE6, the phosphodiesterase present in retinal photoreceptor cells. This is a qualitative difference rather than an absolute one; visual effects remain possible at higher vardenafil doses.
The combination of Levitra with any nitrate medication — in any form and at any dose — is absolutely contraindicated and potentially fatal. Both nitrates and PDE5 inhibitors independently lower blood pressure through nitric oxide pathways; their combination produces a catastrophic and unpredictable drop in blood pressure that can result in myocardial infarction, stroke, severe hypotension, and death. This is the single most important safety fact about every PDE5 inhibitor. Nitrates include nitroglycerin tablets, sublingual sprays, transdermal patches, isosorbide mononitrate, isosorbide dinitrate, and recreational amyl nitrite ("poppers"). If you are prescribed a nitrate for any reason, you cannot take Levitra. This restriction has no exceptions.
A rare but serious adverse event — sudden loss of vision in one or both eyes — has been reported in a small number of patients taking PDE5 inhibitors, including vardenafil. This condition, known as non-arteritic anterior ischemic optic neuropathy (NAION), involves a sudden decrease in blood supply to the optic nerve. A causal relationship between PDE5 inhibitor use and NAION has not been established with certainty; many affected patients had pre-existing risk factors including small optic disc anatomy ("disc at risk"), hypertension, diabetes, hyperlipidemia, and cardiovascular disease. However, the FDA has required labeling updates to include this warning. Any sudden decrease or loss of vision in one or both eyes during or after taking Levitra requires immediate cessation of the medication and urgent ophthalmological evaluation. Do not restart the medication without physician clearance.
Sudden decrease or loss of hearing, sometimes accompanied by tinnitus and dizziness, has been reported with PDE5 inhibitors including vardenafil. As with NAION, a direct causal link has not been conclusively established, but the FDA requires labeling to reflect this risk. Any sudden change in hearing during or following Levitra use warrants immediate medical evaluation and cessation of the medication pending physician review.
Priapism — a prolonged, painful erection lasting more than four hours in the absence of sexual stimulation — is a medical emergency. Left untreated, priapism can cause permanent erectile tissue damage and irreversible ED. While rare with vardenafil at therapeutic doses, it is documented, and the risk is elevated in men with conditions predisposing to priapism including sickle cell anemia, multiple myeloma, and leukemia. Any erection lasting more than four hours requires immediate emergency medical care, regardless of the absence of pain. Delay in treatment is directly correlated with permanent damage.
Sexual activity itself carries a cardiovascular burden — comparable in metabolic demand to climbing two flights of stairs. In patients with significant cardiovascular disease, the cardiac stress of sexual activity — not the PDE5 inhibitor itself — is the primary risk. Levitra is not appropriate for patients for whom sexual activity is inadvisable due to cardiovascular status, including those with unstable angina, recent myocardial infarction (within 90 days), recent stroke, uncontrolled hypertension, or severe heart failure. Cardiovascular risk assessment before initiating PDE5 inhibitor therapy is a standard component of responsible prescribing, particularly in men over 50 with multiple cardiovascular risk factors.
Vardenafil prolongs the cardiac QT interval to a mild degree at standard doses. While clinically insignificant in most patients, this effect is relevant in patients with congenital long QT syndrome, those taking Class IA or Class III antiarrhythmic medications, or those with electrolyte abnormalities. Levitra should be used with particular caution in these patients and is avoided in congenital long QT syndrome.
| Interaction | Mechanism | Clinical Consequence | Management |
|---|---|---|---|
| Nitrates (all forms) | Additive nitric oxide pathway vasodilation | Severe, potentially fatal hypotension — blood pressure drop can be catastrophic and unpredictable | Absolute contraindication. No exceptions. Includes sublingual, oral, transdermal, inhaled, and recreational nitrites ("poppers"). |
| Alpha-blockers | Additive blood pressure lowering | Symptomatic hypotension, dizziness, and syncope — particularly with tamsulosin and other non-selective alpha-blockers | Start Levitra at 5 mg if on alpha-blocker therapy. Tamsulosin 0.4 mg once daily may be used with caution. Avoid Staxyn with alpha-blockers entirely. |
| Strong CYP3A4 inhibitors | Dramatically reduced vardenafil metabolism ? elevated plasma levels | Up to 49-fold increase in vardenafil AUC with ritonavir; 15-fold increase with ketoconazole 400 mg. Severe hypotension and adverse effect amplification. | Ritonavir or other HIV protease inhibitors: maximum 2.5 mg per 72 hours. Ketoconazole 400 mg or itraconazole 400 mg: maximum 2.5 mg per 24 hours. Ketoconazole 200 mg: maximum 5 mg per 24 hours. |
| Moderate CYP3A4 inhibitors | Reduced vardenafil metabolism | Approximately 4-fold increase in vardenafil AUC with erythromycin | Consider maximum 5 mg per dose with erythromycin, clarithromycin, fluconazole. Disclose all medications to prescriber. |
| CYP3A4 inducers | Accelerated vardenafil metabolism ? reduced plasma levels | Substantially reduced vardenafil effect — treatment may appear ineffective | Examples: rifampicin, carbamazepine, phenytoin, St John's Wort. Inform prescriber; dose adjustment or alternative agent may be needed. |
| Other PDE5 inhibitors | Additive PDE5 inhibition and vasodilation | Significantly amplified blood pressure lowering and adverse effects | Contraindicated. Do not combine with sildenafil, tadalafil, or avanafil. |
| Antihypertensive medications | Additive blood pressure lowering | Enhanced hypotensive effect — dizziness, lightheadedness, syncope | Disclose all antihypertensive therapy before starting Levitra. Monitor blood pressure; may require dose adjustment of either agent. |
| Class IA / III antiarrhythmics | Additive QT prolongation | Increased risk of serious cardiac arrhythmia including torsades de pointes | Avoid combination with quinidine, procainamide, amiodarone, sotalol. Cardiologist review required before considering use. |
| Alcohol | Additive vasodilation and blood pressure lowering | Enhanced flushing, dizziness, and hypotension; increased fall risk. Excessive alcohol also impairs erectile function independently. | Limit alcohol to no more than 2 standard drinks when taking Levitra. Heavy drinking should be avoided entirely on dosing days. |
| Grapefruit juice | CYP3A4 inhibition in the gut wall | Increased vardenafil plasma concentrations — risk of amplified adverse effects | Avoid grapefruit and grapefruit juice throughout the day when Levitra is taken. |
If you take any form of nitrate medication — including nitroglycerin (GTN) tablets or spray, isosorbide mononitrate, isosorbide dinitrate, or use recreational amyl nitrite or butyl nitrite ("poppers") — you must not take Levitra under any circumstances. This is not a caution or a "use with care" instruction — it is an absolute contraindication. The blood pressure drop from combining nitrates with any PDE5 inhibitor can be fatal. If you are unsure whether any medication you take is a nitrate, ask your pharmacist or physician before taking Levitra.
Nitrate therapy: Absolute contraindication, as described above. Any patient taking nitrates in any form, for any indication, cannot take Levitra.
Severe cardiovascular disease: Levitra is contraindicated in men for whom sexual activity is medically inadvisable — including those with unstable angina, recent myocardial infarction (within the past 90 days), recent stroke or transient ischemic attack (within the past 6 months), uncontrolled hypertension (systolic >170 mmHg or diastolic >100 mmHg), and severe symptomatic heart failure (NYHA Class IV). Physicians should apply the Princeton Consensus recommendations for cardiovascular risk stratification before prescribing PDE5 inhibitors.
Congenital QT prolongation or hereditary degenerative retinal disorders: Levitra should not be used in patients with congenital long QT syndrome. Patients with hereditary degenerative retinal disorders such as retinitis pigmentosa — who may have a proportion of retinal PDE with structural differences — should exercise caution as safety has not been formally established.
Severe hepatic impairment (Child-Pugh C): Levitra has not been adequately studied in this population. Its use is not recommended.
Women: Levitra is not indicated in women. It has been studied in women with sexual dysfunction (particularly female sexual arousal disorder) but is not FDA-approved for female use.
Pediatric patients: Levitra is contraindicated in patients under 18 years of age. It has no established safety or efficacy profile in pediatric populations.
Known hypersensitivity: Patients with a documented hypersensitivity or allergic reaction to vardenafil or any component of the Levitra formulation should not take the medication.
Disclose your complete medication list to your prescribing physician before starting Levitra — particularly any nitrates, alpha-blockers, antihypertensives, antifungals, HIV protease inhibitors, or antiarrhythmic medications. The drug interaction profile of vardenafil is clinically significant and several interactions require specific dose adjustments rather than simple avoidance.
Never take more than one dose within 24 hours. If a dose does not produce the desired effect, the correct response is to discuss the outcome with your physician — not to take a second dose on the same day or in combination with another PDE5 inhibitor. Response may improve with dose adjustment, timing adjustment, or a switch to a different PDE5 inhibitor.
Allow adequate time before activity. Taking Levitra and expecting an immediate response is a common source of apparent treatment failure. The medication requires 25–60 minutes to reach therapeutic plasma concentrations. Plan the dosing window consistently and allow sexual stimulation to initiate naturally.
Avoid high-fat meals before dosing. If you plan to eat before sexual activity, a light meal is preferable. A heavy or high-fat meal significantly delays absorption and reduces peak plasma concentration, reducing both onset speed and the reliability of the response.
Seek immediate medical attention for any erection lasting longer than four hours, any sudden change in vision or hearing, any episode of chest pain, severe dizziness, or fainting following a dose. These events require same-day emergency evaluation.
Store correctly. Levitra tablets should be stored at room temperature (20–25°C / 68–77°F), away from moisture, light, and heat. Do not store in a bathroom medicine cabinet where heat and humidity are common. Keep out of reach of children.
In the United States, Levitra is a prescription medication available from any licensed pharmacy following a physician consultation. Generic vardenafil — bioequivalent to branded Levitra and substantially more affordable — has been available since 2018 and is the standard dispensed form in most clinical settings today. Telehealth platforms offering ED consultations with licensed physicians have expanded significantly in recent years, allowing many patients to obtain a prescription and have generic vardenafil delivered discreetly to their home following a brief video or asynchronous consultation.
The same prescription requirement applies internationally. In the United Kingdom, Canada, Australia, and throughout Europe, vardenafil is a prescription-only medication dispensed by regulated pharmacies. While Levitra is available from numerous online sources without a prescription requirement, these unregulated vendors operate outside pharmaceutical oversight — creating real risks of counterfeit product, incorrect active ingredient concentration, adulteration, and undisclosed ingredients. A medication that lowers blood pressure — particularly one with an absolute nitrate contraindication — sourced from an unverified supplier is a genuine safety hazard, not merely a regulatory inconvenience.
My Online Med Shop provides genuine, verified Levitra and generic vardenafil sourced exclusively from verified pharmaceutical manufacturers — with free home delivery, discreet packaging, secure encrypted checkout, and 24/7 customer support for every order.
Both Levitra (vardenafil) and Viagra (sildenafil) are PDE5 inhibitors that work through the same core mechanism. Vardenafil is approximately 10 times more potent at the PDE5 receptor than sildenafil, allowing a smaller milligram dose to produce equivalent effect. Vardenafil also has lower activity at PDE6 — the retinal enzyme responsible for sildenafil's characteristic visual disturbances — making visual side effects somewhat less common at standard doses. In practice, clinical differences between the two for most patients are modest; the choice between them often comes down to individual patient response, which can vary meaningfully between agents even at equivalent receptor potency.
Levitra's therapeutic window for erectile response lasts approximately 4 to 5 hours following the dose. This is shorter than Cialis (tadalafil), which can last up to 36 hours, but comparable to Viagra and longer than some patients experience with zaleplon or shorter-acting agents. The 4–5 hour window represents the period during which sexual stimulation is most likely to produce a reliable erectile response — it does not mean an erection is maintained continuously for this period. Sexual stimulation is required for each attempt at intercourse within the window.
Moderate alcohol consumption — up to two standard drinks — is generally considered acceptable alongside a Levitra dose for most patients, but should be approached with caution. Both alcohol and vardenafil independently lower blood pressure, and their combination can produce additive vasodilation resulting in dizziness, flushing, and symptomatic hypotension, particularly when standing up. Heavy alcohol consumption should be avoided entirely on days when Levitra is taken, as it also independently impairs the erectile mechanism, potentially negating the drug's therapeutic benefit. Patients on antihypertensive medications face amplified risk from this combination and should exercise additional caution.
No. Levitra is a physiological facilitator — it acts on the vascular mechanism of erection but has no effect on libido, sexual desire, or arousal. It does not create sexual interest where none exists. Patients who lack libido or have testosterone deficiency require evaluation for the underlying hormonal or psychological cause rather than PDE5 inhibitor treatment, as vardenafil will produce no meaningful benefit in the absence of sexual stimulation and genuine desire.
Apparent non-response to Levitra is common on first use and does not indicate that PDE5 inhibitor therapy is ineffective. Common reasons include: insufficient time between dosing and sexual activity (less than 25–30 minutes); taking the medication after a high-fat meal; inadequate sexual stimulation; anxiety interfering with the natural arousal process; or a dose that is subtherapeutic for the individual patient. If 10 mg has been tried at least four to eight times under appropriate conditions without response, discuss dose escalation to 20 mg with your physician, or consider trialing a different PDE5 inhibitor — response varies between agents for individual patients.
It depends on the nature and severity of the cardiovascular disease. Levitra is contraindicated in patients whose cardiovascular condition makes sexual activity inadvisable — including those with unstable angina, recent myocardial infarction or stroke, uncontrolled hypertension, or severe heart failure. For patients with stable, well-controlled cardiovascular disease, PDE5 inhibitor therapy may be appropriate following formal cardiovascular risk stratification by a physician — typically following the Princeton Consensus Guidelines. The decision must be individualized and physician-guided. Never self-prescribe Levitra if you have any history of cardiac disease without explicit medical clearance.
Levitra independently lowers blood pressure as part of its mechanism of action. When combined with antihypertensive medications — including ACE inhibitors, ARBs, beta-blockers, calcium channel blockers, and diuretics — the blood pressure-lowering effect is additive. For most patients with well-controlled hypertension on stable antihypertensive therapy, Levitra is used safely under physician supervision, often beginning at the lower 5 mg dose to establish tolerability. The most significant concern arises with alpha-blockers, which produce a more pronounced additive effect — always disclose alpha-blocker use before starting Levitra.
Both contain vardenafil as the active ingredient. Levitra is a standard film-coated tablet, available in 2.5, 5, 10, and 20 mg strengths. Staxyn is an orally disintegrating tablet (ODT) at a fixed 10 mg dose — it dissolves on the tongue without water, offering convenience for patients who prefer not to swallow tablets. The formulations are not clinically interchangeable milligram-for-milligram: Staxyn's ODT formulation produces a modestly higher peak plasma concentration (Cmax approximately 21% higher) than the standard tablet at the same dose, and the overall AUC is also slightly higher. Staxyn should not be substituted for Levitra 10 mg without physician awareness of this difference.
Levitra is approved for on-demand use — taken before anticipated sexual activity — not as a daily fixed-dose regimen. The maximum approved frequency is once every 24 hours. Unlike tadalafil, which has an FDA-approved daily low-dose regimen (2.5–5 mg/day) that allows spontaneous sexual activity without planning around a dosing window, vardenafil is not approved in a daily formulation. Patients who prefer the convenience of daily dosing without scheduling around medication timing should discuss daily tadalafil with their physician as an alternative.
Yes. Generic vardenafil is required by FDA standards to be bioequivalent to branded Levitra — producing the same active ingredient concentration in the bloodstream within the same timeframe, within an accepted pharmacokinetic margin. In clinical practice, generic vardenafil is considered therapeutically interchangeable with branded Levitra. It is manufactured by multiple licensed pharmaceutical companies and is available at a significantly lower cost than the branded product, making it the standard dispensed form in most pharmacy settings following patent expiration in 2018.
Levitra (vardenafil) is a well-established, FDA-approved treatment for erectile dysfunction that has been used clinically for over two decades with a consistent and well-characterized efficacy and safety profile. Its potent PDE5 inhibition, comparatively favorable selectivity profile with lower visual side effect incidence than sildenafil, rapid 25–60 minute onset, and reliable 4–5 hour therapeutic window have made it a valued option within the PDE5 inhibitor class — one that suits the needs of many patients for whom other agents have been suboptimal or produced unacceptable adverse effects.
The availability of generic vardenafil since 2018 has significantly improved accessibility, removing cost as a barrier for many patients and making this effective treatment available at a fraction of the original branded price. For the millions of men in the United States and worldwide who experience erectile dysfunction — a condition with significant implications for psychological wellbeing, relationship satisfaction, and in some cases, an early signal of underlying vascular disease — access to a safe, effective, and affordable pharmacological treatment represents a meaningful quality-of-life benefit.
Safe use of Levitra rests on three pillars that cannot be overstated: a valid prescription following proper medical evaluation, absolute adherence to the nitrate contraindication with no exceptions, and sourcing from a verified, regulated pharmaceutical supplier. Within these parameters, vardenafil has an established record as a safe, effective, and well-tolerated treatment for erectile dysfunction across a broad range of patient presentations and comorbidities.
Levitra (Verdanafil)
Buy Zopiclone Online USA: Complete Dosage, Safety & Usage Guide 2026
Buy Modafinil Online USA: Uses, Dosage & Safety Guide 2026
Buy Zopiclone Online